Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations

Published:2020-06 Issue:6 Volume:15 Page:914-947
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Remon Jordi,Passiglia Francesco,Ahn Myung-Ju,Barlesi Fabrice,Forde Patrick M.,Garon Edward B.,Gettinger Scott,Goldberg Sarah B.,Herbst Roy S.,Horn Leora,Kubota Kaoru,Lu Shun,Mezquita Laura,Paz-Ares Luis,Popat Sanjay,Schalper Kurt A.,Skoulidis Ferdinandos,Reck Martin,Adjei Alex A.,Scagliotti Giorgio V.

Funder

MSD

Boehringer Ingelheim

Bristol-Myers Squibb

AstraZeneca

Roche

Pfizer

AbbVie

Amgen

Bayer

F. Hoffmann-La Roche

Genentech

Ipsen

Ignyta

Novartis

Medimmune

Merck

Pierre Fabre

Sanofi

Kyowa Hakko Kirin

EMD Serono

BMS

Lilly

Takeda

ARIAD

Eli Lilly and Company

Genómica

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference284 articles.

1. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer;Horn;N Engl J Med,2018

2. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater;Reck;J Clin Oncol,2019

3. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial;Mok;Lancet,2019

4. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer;Gandhi;N Engl J Med,2018

5. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer;Paz-Ares;N Engl J Med,2018

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy in potentially resectable stage IIIA/IIIB non-small cell lung cancer: Neo-Pre-IC, a single-arm phase 2 trial;eClinicalMedicine;2024-02

2. Targeting Angiogenesis Alone and in Combination with Immune Checkpoint Inhibitors in Advanced Gastroesophageal Malignancies;Current Gastroenterology Reports;2024-01-31

3. DCs targeted therapy expands CD8 T cell responses to bona-fide neoantigens in lung tumors;2024-01-30

4. Cardiac magnetic resonance‐based layer‐specific strain in immune checkpoint inhibitor‐associated myocarditis;ESC Heart Failure;2024-01-19

5. Integration of multi-omics and clinical treatment data reveals bladder cancer therapeutic vulnerability gene combinations and prognostic risks;Frontiers in Immunology;2024-01-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3